Dr. Nabil Dib, MD
Interventional Cardiology (Interventional Cardiology Physician)
3420 S Mercy Rd Ste 312
Gilbert, AZ 85297
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 41
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 305
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Interventional Cardiology Physician primary
AZ license 27731
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Josephs Hospital and Medical Center Phoenix, AZ
- Chandler Regional Medical Center Chandler, AZ
- Mercy Gilbert Medical Center Gilbert, AZ
Medical groups
- Sjhmc Physician Services (646 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 305
- Services billed
- 802
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 329 | 199 |
| Established patient office or other outpatient visit, 30-39 minutes | 241 | 160 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 111 | 102 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 58 | 58 |
| New patient office or other outpatient visit, 45-59 minutes | 46 | 46 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 42 | 42 |
| New patient office or other outpatient visit, 30-44 minutes | 33 | 33 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metoprolol Succinate Other prescribers in Gilbert, AZ | 39 |
| Atorvastatin Calcium Other prescribers in Gilbert, AZ | 35 |
| Amlodipine Besylate Other prescribers in Gilbert, AZ | 33 |
| Eliquis (apixaban) Other prescribers in Gilbert, AZ | 27 |
| Isosorbide Mononitrate Er (isosorbide mononitrate) Other prescribers in Gilbert, AZ | 20 |
| Losartan Potassium Other prescribers in Gilbert, AZ | 19 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Gilbert, AZ | 18 |
| Entresto (sacubitril/valsartan) Other prescribers in Gilbert, AZ | 14 |
| Ezetimibe Other prescribers in Gilbert, AZ | 13 |
| Lisinopril Other prescribers in Gilbert, AZ | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 8 payments worth $449 in total to this clinician.
| Asahi Intecc USA, Inc. | $122 |
|---|---|
| Angiodynamics, Inc. | $103 |
| Cardiac Dimensions, Inc. | $96.68 |
| Mimedx Group, Inc. | $46.30 |
| Abiomed | $42.09 |
| Abbott Laboratories | $19.71 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.53 |
| Food and Beverage | $449 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 6 companies. The companies reported $520,032 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)
Janssen Research & Development, LLC - A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fi…
Janssen Research & Development, LLC - A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction
Merck Sharp & Dohme LLC - Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Alnylam Pharmaceuticals Inc. - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Novartis Pharmaceuticals Corporation - Study name not reported
Eli Lilly and Company - NCT03309332--AMPLATZER PFO Occluder Post Approval Study
Abbott Laboratories
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.